Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01365455
First received: June 1, 2011
Last updated: October 22, 2014
Last verified: October 2014
  Purpose

This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.


Condition Intervention Phase
Moderate to Severe Plaque-type Psoriasis
Drug: secukinumab 150 mg
Drug: placebo to secukinumab 150 mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Number of patients who achieve >75 or higher (Psoriasis Area and Severity Index) PASI score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Measure: PASI score

  • Number of patients who achieve (Investigator's Global Assessment) IGA scor of 0 or 1 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Number of patients who achieve (Investigator's Global Assessment) IGA scor of 0 or 1 as an indicator of efficacy of efficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis


Secondary Outcome Measures:
  • Number of patients who achieve >75 or higher. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Number of patients who achieve >75 or higher (Psoriasis Area and Severity Index) PASI score to measure efficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis

  • Clinical safety and tolerability of secukinumab [ Time Frame: 12 and 52 weeks ] [ Designated as safety issue: Yes ]
    Measure: vital signs, clinical laboratory variables, ECGs, adverse events

  • Quality of life assessments [ Time Frame: 12 and 52 weeks ] [ Designated as safety issue: No ]
    Measure: Patient reported outcome questionnaires

  • Number of patients with a IGA score of 0 or 1 [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Number of patients who achieve (Investigator's Global Assessment) IGA scor of 0 or 1 as an indicator of efficacy of efficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis


Enrollment: 739
Study Start Date: June 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: secukinumab 150 mg
secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose)
Drug: secukinumab 150 mg
secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose); secukinumab 150 mg (2 injection per does)
Experimental: secukinumab 300 mg
secukinumab 150 mg (2 injections per dose)
Drug: secukinumab 150 mg
secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose); secukinumab 150 mg (2 injection per does)
Placebo Comparator: placebo
placebo to secukinumab 150 mg (2 injections per dose)
Drug: placebo to secukinumab 150 mg
placebo to secukinumab 150 mg (2 injections per dose)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.
  • Severity of psoriasis disease meeting all of the following three criteria:
  • Psoriasis Area and Severity Index (PASI) score of 12 or greater,
  • Investigator's Global Assessment (IGA) score of 3 or greater,
  • Total body surface area (BSA) affected of 10% or greater.
  • Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.

Exclusion criteria:

  • Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).
  • Current drug-induced psoriasis.
  • Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.
  • Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject.
  • Hematological abnormalities.
  • History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.
  • History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.
  • Pregnant or nursing (lactating) women.
  • Subjects not willing to limit UV light exposure during the study Other protocol-defined inclusion/exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01365455

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Birmingham, Alabama, United States, 35205
Novartis Investigative Site
Birmingham, Alabama, United States, 35233
United States, Arizona
Novartis Investigative Site
Phoenix, Arizona, United States, 85032
United States, California
Novartis Investigative Site
Los Angeles, California, United States, 90045
Novartis Investigative Site
Oceanside, California, United States, 92056
Novartis Investigative Site
Pasadena, California, United States, 91105
Novartis Investigative Site
San Diego, California, United States, 92123
United States, Colorado
Novartis Investigative Site
Colorado Springs, Colorado, United States, 80915
United States, Florida
Novartis Investigative Site
Boca Raton, Florida, United States, 33486
United States, Georgia
Novartis Investigative Site
Snellville, Georgia, United States, 30078
United States, Indiana
Novartis Investigative Site
Evansville, Indiana, United States, 47713
United States, Kansas
Novartis Investigative Site
Topeka, Kansas, United States, 66606
United States, Kentucky
Novartis Investigative Site
Louisville, Kentucky, United States, 40291
Novartis Investigative Site
Louisville, Kentucky, United States, 40202
United States, Michigan
Novartis Investigative Site
Ann Arbor, Michigan, United States, 48109
Novartis Investigative Site
Ann Arbor, Michigan, United States, 48103
United States, Nebraska
Novartis Investigative Site
Omaha, Nebraska, United States, 68144
United States, New York
Novartis Investigative Site
New York, New York, United States, 10029
Novartis Investigative Site
Rochester, New York, United States, 14623
United States, Oregon
Novartis Investigative Site
Oregon City, Oregon, United States, 97045
Novartis Investigative Site
Portland, Oregon, United States, 97223
Novartis Investigative Site
Portland, Oregon, United States, 97210
United States, Pennsylvania
Novartis Investigative Site
Duncansville, Pennsylvania, United States, 16635
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Novartis Investigative Site
Charleston, South Carolina, United States, 29407
United States, Tennessee
Novartis Investigative Site
Nashville, Tennessee, United States, 37203
United States, Texas
Novartis Investigative Site
Austin, Texas, United States, 78759
Novartis Investigative Site
Bryan, Texas, United States, 77802
Novartis Investigative Site
Dallas, Texas, United States, 75231
Novartis Investigative Site
Dallas, Texas, United States, 75246-1613
Novartis Investigative Site
Houston, Texas, United States, 77030
Novartis Investigative Site
San Antonio, Texas, United States, 78229
United States, Utah
Novartis Investigative Site
Salt Lake City, Utah, United States, 84117
United States, Virginia
Novartis Investigative Site
Norfolk, Virginia, United States, 23507
Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1122AAF
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1181ACH
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1425AWC
Novartis Investigative Site
Mendoza, Argentina, M5502EZA
Canada, New Brunswick
Novartis Investigative Site
Moncton, New Brunswick, Canada, E1C 8X3
Canada, Ontario
Novartis Investigative Site
Hamilton, Ontario, Canada, L8N 1V6
Novartis Investigative Site
Peterborough, Ontario, Canada, K9J 1Z2
Novartis Investigative Site
Waterloo, Ontario, Canada, N2J 1C4
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H3H 1V4
Colombia
Novartis Investigative Site
Barranquilla, Atlantico, Colombia
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Bucaramanga, Colombia
Estonia
Novartis Investigative Site
Tallinn, Estonia, 10617
Novartis Investigative Site
Tallinn, Estonia, 10138
Novartis Investigative Site
Tallinn, Estonia, 13419
Novartis Investigative Site
Tartu, Estonia, 51014
Iceland
Novartis Investigative Site
Kopavogur, Iceland, IS-201
Israel
Novartis Investigative Site
Afula, Israel, 18101
Novartis Investigative Site
Petach Tikva, Israel, 49100
Novartis Investigative Site
Ramat Gan, Israel, 52621
Japan
Novartis Investigative Site
Nagoya-city, Aichi, Japan, 467-8602
Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan, 814-0180
Novartis Investigative Site
Kurume, Fukuoka, Japan, 830-0011
Novartis Investigative Site
Maebashi-city, Gunma, Japan, 371-8511
Novartis Investigative Site
Asahikawa-city, Hokkaido, Japan, 078-8510
Novartis Investigative Site
Sapporo-city, Hokkaido, Japan, 060-0063
Novartis Investigative Site
Kobe-City, Hyogo, Japan, 654-0155
Novartis Investigative Site
Inashiki-gun, Ibaraki, Japan, 300-0395
Novartis Investigative Site
Isehara-city, Kanagawa, Japan, 259-1193
Novartis Investigative Site
Kawasaki-city, Kanagawa, Japan, 213-8507
Novartis Investigative Site
Sagamihara-city, Kanagawa, Japan, 228-8522
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan, 113-8655
Novartis Investigative Site
Chiyoda-ku, Tokyo, Japan, 102-8798
Novartis Investigative Site
Minato-ku, Tokyo, Japan, 105-8471
Novartis Investigative Site
Shinagawa-ku, Tokyo, Japan, 141-8625
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 160-0023
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 160-8582
Novartis Investigative Site
Kyoto, Japan, 602-8566
Latvia
Novartis Investigative Site
Daugavpils, Latvia, LV-5404
Novartis Investigative Site
Riga, Latvia, LV-1001
Novartis Investigative Site
Riga, Latvia, 1012
Novartis Investigative Site
Ventspils, Latvia, LV-3601
Lithuania
Novartis Investigative Site
Kaunas, Lithuania, 50009
Novartis Investigative Site
Klaipeda, Lithuania, 92304
Novartis Investigative Site
Vilnius, Lithuania, LT-07195
Novartis Investigative Site
Vilnius, Lithuania, LT-08661
Mexico
Novartis Investigative Site
México, Distrito Federal, Mexico, 06780
Novartis Investigative Site
México, Distrito Federal, Mexico, 14050
Novartis Investigative Site
Zapopan, Jalisco, Mexico, 45190
Novartis Investigative Site
Monterrey, Nuevo León, Mexico, 64460
Taiwan
Novartis Investigative Site
Hsin Chu, Taiwan
Novartis Investigative Site
Taichung, Taiwan, 40447
Novartis Investigative Site
Taipei, Taiwan, 10002
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Director: Novartis Pharmceuticals Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01365455     History of Changes
Other Study ID Numbers: CAIN457A2302, 2010-023512-13
Study First Received: June 1, 2011
Last Updated: October 22, 2014
Health Authority: United States: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Canada: Health Canada
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Estonia: The State Agency of Medicine
Iceland: Icelandic Medicines Control Agency
Israel: Ministry of Health
Japan: Ministry of Health, Labor and Welfare
Latvia: State Agency of Medicines
Lithuania: State Medicine Control Agency - Ministry of Health
Mexico: Federal Commission for Sanitary Risks Protection
Panama: Ministry of Health
Peru: Ministry of Health
Russia: Ministry of Health of the Russian Federation
Taiwan: Department of Health

Keywords provided by Novartis:
Psoriasis
plaque
plaque-type psoriasis
IL-17 blocker
subcutaneous
psoriatic arthritis
injection
AIN457
AIN457A
secukinumab

Additional relevant MeSH terms:
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Antibodies, Monoclonal
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 19, 2014